In recent years, prostate‐specific membrane antigen (PSMA) imaging has emerged as a more sensitive and efficacious method in PC detection.6, 7 However, few studies have reported the value of PSMA imaging for evaluating the response to PC treatment.8, 9 The positron‐emission tomography (PET) response criteria in solid tumors (PERCIST) 1.0 criteria, which these studies adapted, were initially proposed for F‐18 fluorodeoxyglucose (FDG) PET.10 Whether this standard is feasible in PSMA imaging remains unclear. The gene discussed is FOLH1; the disease is pachyonychia congenita.